Skip to main content
GLOBAL REGULATORY AGENCIES

Generate Submissions for Any Regulatory Agency

DossiAIr supports agency-specific formatting, templates, and regulatory requirements for FDA, EMA, PMDA, NMPA, Health Canada, TGA, MHRA, and other global authorities. Generate compliant eCTD submissions tailored to each agency's unique standards.

Major Regulatory Authorities

Full support for the world's leading pharmaceutical regulatory agencies

πŸ‡ΊπŸ‡Έ

FDA

United States
Food and Drug Administration

World's most influential regulatory agency with rigorous standards for NDA, BLA, and ANDA submissions.

Submission Types:
NDA (New Drug Application)BLA (Biologics License Application)ANDA (Abbreviated NDA)IND (Investigational New Drug)
Review Timeline
Standard Review: 10 months, Priority Review: 6 months
πŸ‡ͺπŸ‡Ί

EMA

European Union
European Medicines Agency

Centralized procedure for marketing authorization across all EU member states, Iceland, Liechtenstein, and Norway.

Submission Types:
MAA (Marketing Authorization Application)Conditional MAAOrphan Drug MAABiosimilar MAA
Review Timeline
Centralized Procedure: 210 days (Day 120 LoQ, Day 180 final questions)
πŸ‡―πŸ‡΅

PMDA

Japan
Pharmaceuticals and Medical Devices Agency

Japanese regulatory authority requiring bilingual submissions and unique CMC requirements for pharmaceutical approvals.

Submission Types:
J-NDA (New Drug Application)ANDA (Generic)Biological Products ApplicationOrphan Drug Application
Review Timeline
Standard Review: 12 months, Priority Review: 6-9 months
πŸ‡¨πŸ‡³

NMPA

China
National Medical Products Administration

Chinese regulatory authority with rapidly evolving requirements and increasing alignment with ICH guidelines.

Submission Types:
NDA (New Drug Application)ANDA (Generic)Imported Drug RegistrationBiological Product Application
Review Timeline
Standard Review: 12-18 months, Priority Review: 6-12 months
πŸ‡¨πŸ‡¦

Health Canada

Canada
Health Canada - Therapeutic Products Directorate

Canadian regulatory authority requiring bilingual (English/French) labeling and eCTD submissions aligned with ICH.

Submission Types:
NDS (New Drug Submission)ANDS (Abbreviated NDS)SNDS (Supplemental NDS)Biologic Drug Submission
Review Timeline
Standard Review: 300 days, Priority Review: 180 days
πŸ‡¦πŸ‡Ί

TGA

Australia
Therapeutic Goods Administration

Australian regulatory authority with streamlined pathways for products already approved by FDA, EMA, or other reference agencies.

Submission Types:
New Chemical Entity RegistrationGeneric Medicine RegistrationBiologicals RegistrationOver-the-Counter Registration
Review Timeline
Standard Review: 255 working days, Priority Review: varies
πŸ‡¬πŸ‡§

MHRA

United Kingdom
Medicines and Healthcare products Regulatory Agency

UK regulatory authority post-Brexit with new pathways independent of EMA while maintaining high scientific standards.

Submission Types:
UK MAAGreat Britain National ProcedureNorthern Ireland AuthorizationReliance Pathway
Review Timeline
Standard Review: 150 days (rolling review available)
πŸ‡¨πŸ‡­

Swissmedic

Switzerland
Swiss Agency for Therapeutic Products

Swiss regulatory authority with high scientific standards and streamlined procedures for products approved by reference agencies.

Submission Types:
Marketing Authorization ApplicationSimplified AuthorizationSpecial AuthorizationOrphan Drug Authorization
Review Timeline
Standard Review: 330 days, Simplified: 140 days

Global Coverage

Support for regulatory agencies across all major pharmaceutical markets

🌎

North America

FDA (USA)
Health Canada
🌍

Europe

EMA (EU)
MHRA (UK)
Swissmedic (Switzerland)
🌏

Asia-Pacific

PMDA (Japan)
NMPA (China)
TGA (Australia)
🌐

Other Markets

COFEPRIS (Mexico)
ANVISA (Brazil)
SAHPRA (South Africa)
CDSCO (India)
KFDA (South Korea)

Agency-Specific Intelligence

Built-in knowledge of unique requirements for each regulatory authority

πŸ“‹

Module 1 Formatting

Agency-specific Module 1 generation with correct forms, cover letters, and administrative documents.

β€’ FDA: Form 356h, User Fee Cover Sheet, Patent Certifications
β€’ EMA: Application Form, QRD templates, Product Information
β€’ PMDA: Application Form, Japanese package insert (ζ·»δ»˜ζ–‡ζ›Έ)
🌐

Language Support

Multi-language document generation and translation for international submissions.

β€’ PMDA: English-Japanese bilingual support
β€’ Health Canada: English-French bilingual labeling
β€’ NMPA: Chinese translation support
πŸ“Š

Data Standards

Compliance with agency-specific data format requirements and standards.

β€’ FDA: CDISC (SDTM, ADaM) for clinical data
β€’ EMA: EudraCT, XEVMPD for product registration
β€’ PMDA: MedDRA Japanese translation (MedDRA/J)
πŸ”

Submission Gateways

Export formats compatible with each agency's electronic submission gateway.

β€’ FDA: ESG (Electronic Submissions Gateway)
β€’ EMA: CESP (Centralized Electronic Submission Platform)
β€’ Health Canada: ECTD Validation Tool
πŸ“

Regulatory Prompts

3,400+ agency-specific regulatory prompts ensure compliance with local guidelines.

β€’ FDA: 21 CFR Part 314 requirements
β€’ EMA: EU GMP Annex requirements
β€’ PMDA: Japanese regulatory guidance
βœ…

Validation Rules

Pre-submission validation against agency-specific technical specifications.

β€’ FDA: ESG business rules validation
β€’ EMA: EU Module 1 validation checks
β€’ ICH: XML backbone validation

Ready for Global Regulatory Success?

See how DossiAIr can generate agency-compliant submissions for FDA, EMA, PMDA, and other global authorities.